Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Aug;37(8):1655–1658. doi: 10.1128/aac.37.8.1655

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

H C Meissner 1, D R Fulton 1, J R Groothuis 1, R L Geggel 1, G R Marx 1, V G Hemming 1, T Hougen 1, D R Snydman 1
PMCID: PMC188036  PMID: 8215279

Abstract

We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. Forty-nine children (mean age at enrollment, 4.5 months) with severe congenital heart disease or bronchopulmonary dysplasia were randomized as follows. Twenty-four patients were followed as controls and received no immune globulin. Twenty-five patients received monthly infusions of immune globulin at a dose of 500 mg/kg of body weight. There was a similar distribution between groups of patients with heart disease and bronchopulmonary dysplasia. There were 12 culture-proven RSV infections, 6 in the prophylaxis group and 6 in the control group. There was a trend toward less severe RSV illness in immune globulin recipients, as measured by length of hospitalization. Four of the six immune globulin recipients were hospitalized for a total of 35 days (mean, 8.8 +/- 5.0 days) because of RSV illness, in contrast to 51 hospital days (mean, 12.8 +/- 7.6 days) among RSV-infected controls. We conclude that monthly infusions of standard immune globulin containing RSV Nt antibodies may be safely administered to high-risk children, but that standard intravenous immune globulin does not contain sufficient RSV Nt antibody titer to fully protect against severe RSV illness.

Full text

PDF
1655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson L. J., Parker R. A., Strikas R. L. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis. 1990 Apr;161(4):640–646. doi: 10.1093/infdis/161.4.640. [DOI] [PubMed] [Google Scholar]
  2. Chin J., Magoffin R. L., Shearer L. A., Schieble J. H., Lennette E. H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969 Apr;89(4):449–463. doi: 10.1093/oxfordjournals.aje.a120957. [DOI] [PubMed] [Google Scholar]
  3. Fulginiti V. A., Eller J. J., Sieber O. F., Joyner J. W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969 Apr;89(4):435–448. doi: 10.1093/oxfordjournals.aje.a120956. [DOI] [PubMed] [Google Scholar]
  4. Glezen W. P., Paredes A., Allison J. E., Taber L. H., Frank A. L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981 May;98(5):708–715. doi: 10.1016/s0022-3476(81)80829-3. [DOI] [PubMed] [Google Scholar]
  5. Groothuis J. R., Gutierrez K. M., Lauer B. A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988 Aug;82(2):199–203. [PubMed] [Google Scholar]
  6. Groothuis J. R., Levin M. J., Rodriguez W., Hall C. B., Long C. E., Kim H. W., Lauer B. A., Hemming V. G. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother. 1991 Jul;35(7):1469–1473. doi: 10.1128/aac.35.7.1469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hall C. B., Kopelman A. E., Douglas R. G., Jr, Geiman J. M., Meagher M. P. Neonatal respiratory syncytial virus infection. N Engl J Med. 1979 Feb 22;300(8):393–396. doi: 10.1056/NEJM197902223000803. [DOI] [PubMed] [Google Scholar]
  8. Hall C. B., McBride J. T. Vapors, viruses, and views. Ribavirin and respiratory syncytial virus. Am J Dis Child. 1986 Apr;140(4):331–332. doi: 10.1001/archpedi.1986.02140180065025. [DOI] [PubMed] [Google Scholar]
  9. Hemming V. G., Prince G. A., Horswood R. L., London W. J., Murphy B. R., Walsh E. E., Fischer G. W., Weisman L. E., Baron P. A., Chanock R. M. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis. 1985 Nov;152(5):1083–1087. doi: 10.1093/infdis/152.5.1083. [DOI] [PubMed] [Google Scholar]
  10. Hemming V. G., Prince G. A. Immunoprophylaxis of infections with respiratory syncytial virus: observations and hypothesis. Rev Infect Dis. 1990 May-Jun;12 (Suppl 4):S470–S475. doi: 10.1093/clinids/12.supplement_4.s470. [DOI] [PubMed] [Google Scholar]
  11. Kapikian A. Z., Mitchell R. H., Chanock R. M., Shvedoff R. A., Stewart C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969 Apr;89(4):405–421. doi: 10.1093/oxfordjournals.aje.a120954. [DOI] [PubMed] [Google Scholar]
  12. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969 Apr;89(4):422–434. doi: 10.1093/oxfordjournals.aje.a120955. [DOI] [PubMed] [Google Scholar]
  13. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969 Apr;89(4):422–434. doi: 10.1093/oxfordjournals.aje.a120955. [DOI] [PubMed] [Google Scholar]
  14. Lamprecht C. L., Krause H. E., Mufson M. A. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis. 1976 Sep;134(3):211–217. doi: 10.1093/infdis/134.3.211. [DOI] [PubMed] [Google Scholar]
  15. MacDonald N. E., Hall C. B., Suffin S. C., Alexson C., Harris P. J., Manning J. A. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982 Aug 12;307(7):397–400. doi: 10.1056/NEJM198208123070702. [DOI] [PubMed] [Google Scholar]
  16. Paisley J. W., Lauer B. A., McIntosh K., Glode M. P., Schachter J., Rumack C. Pathogens associated with acute lower respiratory tract infection in young children. Pediatr Infect Dis. 1984 Jan-Feb;3(1):14–19. doi: 10.1097/00006454-198401000-00005. [DOI] [PubMed] [Google Scholar]
  17. Parrott R. H., Kim H. W., Arrobio J. O., Hodes D. S., Murphy B. R., Brandt C. D., Camargo E., Chanock R. M. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973 Oct;98(4):289–300. doi: 10.1093/oxfordjournals.aje.a121558. [DOI] [PubMed] [Google Scholar]
  18. Prince G. A., Hemming V. G., Horswood R. L., Chanock R. M. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985 Oct;3(3):193–206. doi: 10.1016/0168-1702(85)90045-0. [DOI] [PubMed] [Google Scholar]
  19. Prince G. A., Horswood R. L., Chanock R. M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol. 1985 Sep;55(3):517–520. doi: 10.1128/jvi.55.3.517-520.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Prince G. A., Jenson A. B., Horswood R. L., Camargo E., Chanock R. M. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol. 1978 Dec;93(3):771–791. [PMC free article] [PubMed] [Google Scholar]
  21. Siber G. R., Snydman D. R. Use of immune globulins in the prevention and treatment of infections. Curr Clin Top Infect Dis. 1992;12:208–256. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES